Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus

Caldés, A. (A.)|||/items/94ed7497-d85a-4a92-af1e-65f4e882ed36; Colom, H. (H.)|||/items/bc43f225-25a0-441e-a0e0-539de3cc89d9; Armendariz, Y. (Y.)|||/items/46f549fb-2955-4234-bb51-06a772da1357; Garrido-Cid, M.J. (María Jesús)|||/items/02b0ddd8-23bb-4f81-8a99-5d1296b3c703; Troconiz, I.F. (Iñaki F.)|||/items/e6782d1e-7a2a-42cc-95d6-55223215bf44; Gil-Vernet, S. (S.)|||/items/1196b9aa-c343-4e85-be62-51fb790e4259; Lloberas, N. (N.)|||/items/2081eb64-206d-4f3e-8cd6-b0bb2a2bbfa0; Pou, L. (L.)|||/items/6e40b772-5dcd-47e7-a78f-489b98bcc9a9; Peraire, C. (Concepción)|||/items/4b20a69b-9272-44dd-954a-cb446dd8784b; Grinyó, J.M. (J. M.)|||/items/bef9745b-064f-4da4-8700-a9e695c87986

Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus

A population pharmacokinetics analysis was performed after intravenous ganciclovir and oral valganciclovir in solid organ transplant patients with cytomegalovirus. Patients received ganciclovir at 5 mg/kg of body weight (5 days) and then 900 mg of valganciclovir (16 days), both twice daily with dose...

Descripción completa

Detalles Bibliográficos
Autores:	Caldés, A. (A.)\|\|\|/items/94ed7497-d85a-4a92-af1e-65f4e882ed36, Colom, H. (H.)\|\|\|/items/bc43f225-25a0-441e-a0e0-539de3cc89d9, Armendariz, Y. (Y.)\|\|\|/items/46f549fb-2955-4234-bb51-06a772da1357, Garrido-Cid, M.J. (María Jesús)\|\|\|/items/02b0ddd8-23bb-4f81-8a99-5d1296b3c703, Troconiz, I.F. (Iñaki F.)\|\|\|/items/e6782d1e-7a2a-42cc-95d6-55223215bf44, Gil-Vernet, S. (S.)\|\|\|/items/1196b9aa-c343-4e85-be62-51fb790e4259, Lloberas, N. (N.)\|\|\|/items/2081eb64-206d-4f3e-8cd6-b0bb2a2bbfa0, Pou, L. (L.)\|\|\|/items/6e40b772-5dcd-47e7-a78f-489b98bcc9a9, Peraire, C. (Concepción)\|\|\|/items/4b20a69b-9272-44dd-954a-cb446dd8784b, Grinyó, J.M. (J. M.)\|\|\|/items/bef9745b-064f-4da4-8700-a9e695c87986
Tipo de recurso:	artículo
Fecha de publicación:	2009
País:	España
Institución:	Universidad de Navarra
Repositorio:	Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:	inglés
OAI Identifier:	oai:dadun.unav.edu:10171/21704
Acceso en línea:	https://hdl.handle.net/10171/21704
Access Level:	acceso abierto
Palabra clave:	Pharmacokinetic Intravenous ganciclovir Oral valganciclovir

id	ES_a82ef319342c3e1d937ab4e4b9789bfb
oai_identifier_str	oai:dadun.unav.edu:10171/21704
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirusCaldés, A. (A.)\|\|\|/items/94ed7497-d85a-4a92-af1e-65f4e882ed36Colom, H. (H.)\|\|\|/items/bc43f225-25a0-441e-a0e0-539de3cc89d9Armendariz, Y. (Y.)\|\|\|/items/46f549fb-2955-4234-bb51-06a772da1357Garrido-Cid, M.J. (María Jesús)\|\|\|/items/02b0ddd8-23bb-4f81-8a99-5d1296b3c703Troconiz, I.F. (Iñaki F.)\|\|\|/items/e6782d1e-7a2a-42cc-95d6-55223215bf44Gil-Vernet, S. (S.)\|\|\|/items/1196b9aa-c343-4e85-be62-51fb790e4259Lloberas, N. (N.)\|\|\|/items/2081eb64-206d-4f3e-8cd6-b0bb2a2bbfa0Pou, L. (L.)\|\|\|/items/6e40b772-5dcd-47e7-a78f-489b98bcc9a9Peraire, C. (Concepción)\|\|\|/items/4b20a69b-9272-44dd-954a-cb446dd8784bGrinyó, J.M. (J. M.)\|\|\|/items/bef9745b-064f-4da4-8700-a9e695c87986PharmacokineticIntravenous ganciclovirOral valganciclovirA population pharmacokinetics analysis was performed after intravenous ganciclovir and oral valganciclovir in solid organ transplant patients with cytomegalovirus. Patients received ganciclovir at 5 mg/kg of body weight (5 days) and then 900 mg of valganciclovir (16 days), both twice daily with dose adjustment for renal function. A total of 382 serum concentrations from days 5 and 15 were analyzed with NONMEM VI. Renal function given by creatinine clearance (CL(CR)) was the most influential covariate in CL. The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h. The CL(CR) was the best predictor of CL, making dose adjustment by this covariate important to achieve the most efficacious ganciclovir exposure.American Society for MicrobiologyDadun. Depósito Académico Digital Universidad de Navarra20122012-04-2020092009-01-0120092009-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/21704reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/217042026-06-21T12:47:57Z
dc.title.none.fl_str_mv	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus
title	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus
spellingShingle	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus Caldés, A. (A.)\|\|\|/items/94ed7497-d85a-4a92-af1e-65f4e882ed36 Pharmacokinetic Intravenous ganciclovir Oral valganciclovir
title_short	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus
title_full	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus
title_fullStr	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus
title_full_unstemmed	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus
title_sort	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus
dc.creator.none.fl_str_mv	Caldés, A. (A.)\|\|\|/items/94ed7497-d85a-4a92-af1e-65f4e882ed36 Colom, H. (H.)\|\|\|/items/bc43f225-25a0-441e-a0e0-539de3cc89d9 Armendariz, Y. (Y.)\|\|\|/items/46f549fb-2955-4234-bb51-06a772da1357 Garrido-Cid, M.J. (María Jesús)\|\|\|/items/02b0ddd8-23bb-4f81-8a99-5d1296b3c703 Troconiz, I.F. (Iñaki F.)\|\|\|/items/e6782d1e-7a2a-42cc-95d6-55223215bf44 Gil-Vernet, S. (S.)\|\|\|/items/1196b9aa-c343-4e85-be62-51fb790e4259 Lloberas, N. (N.)\|\|\|/items/2081eb64-206d-4f3e-8cd6-b0bb2a2bbfa0 Pou, L. (L.)\|\|\|/items/6e40b772-5dcd-47e7-a78f-489b98bcc9a9 Peraire, C. (Concepción)\|\|\|/items/4b20a69b-9272-44dd-954a-cb446dd8784b Grinyó, J.M. (J. M.)\|\|\|/items/bef9745b-064f-4da4-8700-a9e695c87986
author	Caldés, A. (A.)\|\|\|/items/94ed7497-d85a-4a92-af1e-65f4e882ed36
author_facet	Caldés, A. (A.)\|\|\|/items/94ed7497-d85a-4a92-af1e-65f4e882ed36 Colom, H. (H.)\|\|\|/items/bc43f225-25a0-441e-a0e0-539de3cc89d9 Armendariz, Y. (Y.)\|\|\|/items/46f549fb-2955-4234-bb51-06a772da1357 Garrido-Cid, M.J. (María Jesús)\|\|\|/items/02b0ddd8-23bb-4f81-8a99-5d1296b3c703 Troconiz, I.F. (Iñaki F.)\|\|\|/items/e6782d1e-7a2a-42cc-95d6-55223215bf44 Gil-Vernet, S. (S.)\|\|\|/items/1196b9aa-c343-4e85-be62-51fb790e4259 Lloberas, N. (N.)\|\|\|/items/2081eb64-206d-4f3e-8cd6-b0bb2a2bbfa0 Pou, L. (L.)\|\|\|/items/6e40b772-5dcd-47e7-a78f-489b98bcc9a9 Peraire, C. (Concepción)\|\|\|/items/4b20a69b-9272-44dd-954a-cb446dd8784b Grinyó, J.M. (J. M.)\|\|\|/items/bef9745b-064f-4da4-8700-a9e695c87986
author_role	author
author2	Colom, H. (H.)\|\|\|/items/bc43f225-25a0-441e-a0e0-539de3cc89d9 Armendariz, Y. (Y.)\|\|\|/items/46f549fb-2955-4234-bb51-06a772da1357 Garrido-Cid, M.J. (María Jesús)\|\|\|/items/02b0ddd8-23bb-4f81-8a99-5d1296b3c703 Troconiz, I.F. (Iñaki F.)\|\|\|/items/e6782d1e-7a2a-42cc-95d6-55223215bf44 Gil-Vernet, S. (S.)\|\|\|/items/1196b9aa-c343-4e85-be62-51fb790e4259 Lloberas, N. (N.)\|\|\|/items/2081eb64-206d-4f3e-8cd6-b0bb2a2bbfa0 Pou, L. (L.)\|\|\|/items/6e40b772-5dcd-47e7-a78f-489b98bcc9a9 Peraire, C. (Concepción)\|\|\|/items/4b20a69b-9272-44dd-954a-cb446dd8784b Grinyó, J.M. (J. M.)\|\|\|/items/bef9745b-064f-4da4-8700-a9e695c87986
author2_role	author author author author author author author author author
dc.contributor.none.fl_str_mv	Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv	Pharmacokinetic Intravenous ganciclovir Oral valganciclovir
topic	Pharmacokinetic Intravenous ganciclovir Oral valganciclovir
description	A population pharmacokinetics analysis was performed after intravenous ganciclovir and oral valganciclovir in solid organ transplant patients with cytomegalovirus. Patients received ganciclovir at 5 mg/kg of body weight (5 days) and then 900 mg of valganciclovir (16 days), both twice daily with dose adjustment for renal function. A total of 382 serum concentrations from days 5 and 15 were analyzed with NONMEM VI. Renal function given by creatinine clearance (CL(CR)) was the most influential covariate in CL. The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h. The CL(CR) was the best predictor of CL, making dose adjustment by this covariate important to achieve the most efficacious ganciclovir exposure.
publishDate	2009
dc.date.none.fl_str_mv	2009 2009-01-01 2009 2009-01-01 2012 2012-04-20
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/10171/21704
url	https://hdl.handle.net/10171/21704
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	American Society for Microbiology
publisher.none.fl_str_mv	American Society for Microbiology
dc.source.none.fl_str_mv	reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra
instname_str	Universidad de Navarra
reponame_str	Dadun. Depósito Académico Digital de la Universidad de Navarra
collection	Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869415857899175936
score	15.300719

Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus

Similares en LA Referencia